We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
It wants to monetise the trade in iboga, which is reputed to help people kick drug addictions
Pharma group blames ‘misinformation’ for overshadowing approval of therapy
UK drugmaker seeks to unlock £400m of private investment for site in Stevenage
Hong Kong-based platform has 16 programmes in development including potential cancer and Covid treatments
Moves to ease market access for generic drugmakers are gaining momentum
Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’
Phase 3 stage shows drug not significantly more effective than placebo
Emer Cooke stressed that depending too heavily on a single shot could be self-defeating
UK pharma group will pay iTeos Therapeutics up to $2.1bn to collaborate on a tumour drug
Sum amassed by Flagship Pioneering is among largest in pharmaceutical industry
US biotech says pandemic has helped it accelerate development of new class of drugs
US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high
Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic
FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy
Biogen’s aducanumab would be first new treatment in years for disease if approved by FDA
New study paves the way for revaccination campaign in the autumn
US pharma company agrees four-year deal with Oxford-based Exscientia
Oxford Cannabinoid Technologies emerged from university research project into potential treatments
Post-jab fatigue and fever more common when second dose is different to the first
New activist shareholder may not have quick answers to drugmaker’s underlying problems
Creation of task force by UK government welcomed but no trials have delivered solutions
Antivirals task force will seek to develop medicines people can take at home
Scientists probe whether adenoviral vectors in AstraZeneca and J&J shots are triggering rare reaction
Global health body warns none of antibiotics currently being developed are enough to tackle superbugs
Regulators say shot is safe but UK records new clotting cases and growing number of countries restrict its use
International Edition
